BALPHARMA
79.85
2019-01-04
BAL PHARMA LTD.
Profitability metrics STANDALONE CONSOLIDATED
Asset Turnover 0.852 0.828
Current ratio 2.22 2.34
WC days 170.17 179.18
EBITDA (%) 11.76 10.19
FCF (Rs Cr.) -0.59 -0.51
ROCE (%) 10.84 8.32
ROE (%) 8.22 4.28

Solvency metrics STANDALONE CONSOLIDATED
Cash Ratio 0.05 0.05
Div. payout (%) 23.91 51.08
Int. Coverage 1.91 1.57
LT D/E 1.26 1.69
Solvency Ratio 0.14 0.09

Valuation STANDALONE CONSOLIDATED
Beta 1.1682 1.1682
Div. yield (%) 1 1
EV (Rs Cr.) 196.31 215.2
P/BV 1.51 1.68
P/E 18.42 39.35
PEG 0.97 0.98
P/S 0.53 0.52

Balance sheet metrics STANDALONE CONSOLIDATED
BV/share 50.97 45.86
3Y growth BV/s (%) 23 11
Cash (Rs Cr.) 4.02 4.15
Total Debt (Rs Cr.) 90.94 109.96
Net block (Rs Cr.) 58.28 70.55

P&L metrics STANDALONE CONSOLIDATED
DPS 1 1
EPS 4.19 1.96
Net Income (Rs Cr.) 5.94 2.78
Operating profit (Rs Cr.) 22.78 17.22
No. of o/s shares 1.417 1.417
Revenue (Rs Cr.) 207.66 209.29
Total Income (Rs Cr.) 209.3 210.99

Cash Flow metrics STANDALONE CONSOLIDATED
CEPS (%) 419 -35
3Y growth CEPS -0.62 -1.03
CFF (Rs Cr.) 3.53 3.55
CFI (Rs Cr.) -10.06 -3.56
CFO (Rs Cr.) 5.94 -0.5
FCF (Rs Cr.) -0.59 -0.51
3Y growth Op. CF (%) -59 -103

Growth metrics STANDALONE CONSOLIDATED
3Y growth dividends (%) 0 2
1Q growth EBITDA (%) 0 0
3Y growth EBITDA (%) 30 17
4Q growth EBITDA (%) 0 0
1Q growth EPS (%) 0 0
3Y growth EPS (%) 34 -29
4Q growth EPS (%) 0 0
3Y growth Net inc. (%) 48 -22
1Y growth Op. CF (%) 9 -109
1Q growth revenue (%) 0 0
3Y growth revenue (%) 11 12
4Q growth revenue (%) 0 0